A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 29 Aug 2017 Status changed from recruiting to completed.
- 12 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 12 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.